Horizon Pharma PLC (NASDAQ:HZNP) – Analysts at Cantor Fitzgerald lowered their FY2018 earnings per share (EPS) estimates for shares of Horizon Pharma PLC in a research report issued to clients and investors on Wednesday. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will post earnings per share of $0.97 for the year, down from their previous forecast of $1.09. Cantor Fitzgerald currently has a “Buy” rating and a $17.00 price target on the stock.
Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.29. The company had revenue of $289.51 million for the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.56 EPS.
WARNING: This story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/09/19/horizon-pharma-plc-to-post-fy2018-earnings-of-0-97-per-share-cantor-fitzgerald-forecasts-hznp.html.
Several other analysts have also commented on the stock. Piper Jaffray Companies set a $18.00 price objective on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Sunday, September 10th. ValuEngine lowered shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Mizuho restated a “hold” rating and issued a $12.00 price objective (up from $9.00) on shares of Horizon Pharma PLC in a report on Monday, August 28th. Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $18.00 target price (up from $17.00) on shares of Horizon Pharma PLC in a report on Thursday, August 10th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $18.67.
Horizon Pharma PLC (HZNP) traded up 0.59% during mid-day trading on Monday, hitting $11.91. The stock had a trading volume of 590,912 shares. The firm’s market capitalization is $1.95 billion. The stock’s 50 day moving average price is $12.81 and its 200 day moving average price is $12.97. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98.
Several institutional investors have recently modified their holdings of the company. Family Management Corp purchased a new position in shares of Horizon Pharma PLC during the 2nd quarter worth $131,000. Proxima Capital Management LLC boosted its stake in shares of Horizon Pharma PLC by 8.1% during the 2nd quarter. Proxima Capital Management LLC now owns 266,311 shares of the biopharmaceutical company’s stock worth $3,161,000 after acquiring an additional 20,000 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Horizon Pharma PLC by 1.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 125,933 shares of the biopharmaceutical company’s stock worth $1,495,000 after acquiring an additional 1,379 shares during the last quarter. State Street Corp boosted its stake in shares of Horizon Pharma PLC by 12.0% during the 2nd quarter. State Street Corp now owns 4,906,307 shares of the biopharmaceutical company’s stock worth $58,241,000 after acquiring an additional 524,187 shares during the last quarter. Finally, Prudential PLC purchased a new position in shares of Horizon Pharma PLC during the 2nd quarter worth $4,027,000. Institutional investors and hedge funds own 82.30% of the company’s stock.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.